PDCD1 and melanoma: Compared with free 5‐ALA, PD‐1 antibody and clinical first‐line chemical drug dacarbazine (DTIC), CAH‐mediated PDT significantly increases curable rate and relapse‐free survival rate in advanced melanoma murine models through long‐term regulation of immune system in the presence of CD4+CD8+ double positive cells.